CBS 2019
CBSMD教育中心
中 文

Stenting Left Main

Abstract

Recommended Article

Expansion or contraction of stenting in coronary artery disease? New-onset atrial fibrillation after PCI and CABG for left main disease: insights from the EXCEL trial and additional studies Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis A Systematic Review and Meta-analysis Radial versus femoral artery access in patients undergoing PCI for left main coronary artery disease: analysis from the EXCEL trial Usefulness of the SYNTAX score II to validate 2-year outcomes in patients with complex coronary artery disease undergoing percutaneous coronary intervention: A large single-center study Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial

Clinical TrialAvailable online 30 October 2017

JOURNAL:J Am Coll Cardiol. Article Link

Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease

SJ Baron, K Chinnakondepalli, EA. Magnuson et al. Keywords: Quality of Life; Left Main Coronary Artery Disease; Percutaneous Coronary Intervention; Bypass Surgery

ABSTRACT


Background - The EXCEL trial compared outcomes in patients with unprotected left main coronary artery disease (LMCAD) treated with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) using everolimus-eluting stents. While rates of death, stroke, and myocardial infarction were similar at 36 months, event timing and repeat revascularization rates differed by treatment group.


Objectives - To understand the effects of revascularization strategy from the patient’s perspective, we performed a prospective quality of life (QoL) sub-study alongside the EXCEL trial.


Methods - Between September 2010 and March 2014, 1905 patients with LMCAD were randomized to undergo CABG or PCI, of whom 1788 participated in the QoL sub-study. QoL was assessed at baseline and 1, 12, and 36 months using the Seattle Angina Questionnaire, the SF-12, the Rose Dyspnea Scale, the Patient Health Questionnaire-8, and the EQ-5D. Differences between PCI and CABG were assessed using longitudinal random-effect growth curve models.


Results - Over 36 months, both PCI and CABG were associated with significant improvements in QoL compared with baseline. At 1 month, PCI was associated with better QoL than CABG. By 12 months though, these differences were largely attenuated, and by 36 months, there were no significant QoL differences between PCI and CABG.


Conclusions - Among selected patients with LMCAD, both PCI and CABG result in similar QoL improvement through 36 months, although a greater early benefit is seen with PCI. Taken together with the 3-year clinical results of EXCEL, these findings suggest that PCI and CABG provide similar intermediate-term outcomes for patients with LMCAD.